WPD Pharmaceuticals : Provides Corporate Updates

PRLog – Global Press Release Distribution

WPD Pharmaceuticals provides company updates

Vancouver, British Columbia – November 18, 2022 – PR log —Provided by WPD Pharmaceuticals

Corporate update

VANCOUVER, British Columbia, November 18, 2022 – WPD Pharmaceuticals Inc. (WBIO) (FSE: 8SV1) (“Company” or “WPD”), a clinical-stage pharmaceutical company, Follow the Substitute Information Guidelines set forth in Trade Orders (“NP 12-203”). In addition to our new release dated September 20, 2022, WPD Pharmaceuticals sp. z oo (“WPD Poland”) is now a wholly-owned subsidiary of the Company and his shares of WPD Poland 34,000 at 50 PLN per share by Houston Pharmaceuticals Inc. (“Houston Pharmaceuticals”) Approved subscription of shares. 1.7 million. Houston Pharmaceuticals contributed the full amount and a statement regarding the acquisition of new shares (a statement required by Polish law) he submitted to WPD Poland. Pursuant to the provisions of the Polish Company Law, the raising of WPD Poland’s share capital and the issuance of new shares will take effect on the date of its registration in the National Register of Courts by the Registrar Court. Upon completion of this funding, Houston Pharmaceuticals will own his 80.95% of WPD Poland’s share capital. Until the moment of registration, the company remains the sole shareholder of his WPD Poland. This funding is of a bridging nature until WPD Pharmaceuticals sp. can obtain additional capital. z oo from capital market investors. The next step of the management board of WPD Pharmaceuticals sp. z

1. Eligible foreign investors from within Poland and from the European Union and the United States interested in participating in the funding of the next stage of development of WPD Pharmaceuticals sp. is to look for zo. o in Poland.

On May 6, 2022, the Company announced that it has filed a petition with the British Columbia Securities Commission (“BCSC”) to approve a temporary ”). The filing of the annual financial statements, management’s discussion and analysis, and required certifications (the “Annual Filings”) for the year ended December 31, 2021 complies with National Instrument 51-102, Continuous Disclosure Obligations and NI 52-109, Certification of Disclosure in Issuer’s Annual and Interim Filings. The application was approved by the BCSC on May 3, 2022 and the MCTO was issued by the BCSC on May 3, 2022. The Company expects that its annual report was filed on or before November 30, 2022 and its interim financial statements for the three months ended March 31, 2022 and the six months ended June 30, 2022 It is expected to be submitted shortly after. .

There are no material changes to the information or other changes contained in the Default Notice that are required to be disclosed under NP 12-203.

We will continue to provide bi-weekly updates as required by NP 12-203 until the annual report is filed. We confirm that we continue to meet the provisions of the Alternative Information Guidelines set forth in Sections 9 and 10 of NP 12-203.

About WPD Pharmaceuticals

WPD is a biotechnology research and development company focused on oncology and virology.

PRLog – Global Press Release Distribution

molecule. WPD has approved nine new drug candidates in selected countries, four of which are in clinical development. These drug candidates are being studied in medical institutions and WPD is currently working with Wake Forest University and major hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., each of which grants WPD a license to certain of Licensor’s technologies. Exclusively sublicensed with royalties. Such agreements provide WPD with certain research, development, manufacturing and marketing rights. Sublicensing territories from CNS Pharmaceuticals and Moleculin Biotech include up to 29 countries in Europe and Asia, including Russia, depending on compound.

On behalf of the Board of Directors

“Marius Orenichuk”

Mariusz Orenichak

CEO, WDP Pharmaceuticals

contact:

PR for investors

Email: investors@wpdpharmaceuticals.com

Phone: 604-428-7050

web: www.wpdpharmaceuticals.com

Notes:

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Authority of Canada make any representations as to the adequacy or accuracy of this release.

This press release contains forward-looking statements. Forward-looking statements are statements that reflect actions, events or developments that we anticipate will occur or may occur in the future. The forward-looking statements in this press release include the following: WPD will complete its financing with Houston Pharmaceuticals; It must be prepared by November 30th and the interim financial statements will be filed shortly thereafter. These forward-looking statements reflect the Company’s current expectations based on information currently available to management and are subject to a number of risks and uncertainties that could cause results to differ materially from expectations. It depends. Factors that could impede the realization of forward-looking statements are that pharmaceutical compounds may not provide the expected benefits and may not be further developed. Competitors or others may challenge granted patents and invalidate them. May not be able to complete financing with Houston Pharmaceuticals, may not be able to complete steps required to prepare annual report by November 30, 2022, and may not file interim financial statements You may not be able to complete the steps required to Readers should refer to the Risk Disclosures contained from time to time in the documents we file with SEDAR available at www.sedar.com. Although we believe the assumptions inherent in these forward-looking statements are reasonable, we do not guarantee future prospects.

PRLog – Global Press Release Distribution

Therefore, they should not be relied upon, and there is no guarantee that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release, and we undertake no obligation to update them, except as required by applicable law. Shall not.

contact

WPD Pharmaceuticals

***@newtechcomm.pl

– – end – –

Scan this QR code with your smartphone to

• read this news online
• contact the author
• Bookmark or share online